Brain metastases, or intracranial metastatic disease (IMD), are a serious and common complication of cancer, occurring in 20% of patients with primary disease.
1 Patients with IMD have a 2-year survival rate of 8.1% and are likely to experience decreases in quality of life from neurologic symptoms associated with their disease or treatment.
2,3 Interest exists in new therapeutic modalities for patients with IMD because of the limitations of available options, such as surgical resection and stereotactic radiosurgery, which are often reserved for patients with good performance status and low tumor burden, or whole-brain radiotherapy, which is associated with neurocognitive decline.
4,5 Targeted therapies have been proposed to fill this gap, despite historical concerns that the benefit of systemic therapies as treatments for IMD has been limited by their inability to penetrate the blood-brain barrier (BBB). The National Comprehensive Cancer Network
6 includes 2 targeted therapies in their most recent IMD treatment guidelines, but the Congress of Neurological Surgeons
7 cites insufficient evidence to recommend the use of targeted therapies in IMD.